Glucocorticoid pathways in chronic obstructive pulmonary disease therapy

Proceedings of the American Thoracic Society

Volumn 2, Issue 4, 2005, Pages 313-319

  Adcock, Ian M ^a   Ito, Kazuhiro ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Glucocorticoid receptor phosphorylation; Inhaled corticosteroids; Oxidative stress; Steroid resistance

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR;

ADRENAL DISEASE; ADRENAL SUPPRESSION; ASTHMA; BONE DENSITY; BONE DISEASE; CATARACT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFERENCE PAPER; DRUG RECEPTOR BINDING; DRUG SENSITIVITY; HUMAN; LUNG FUNCTION; OXIDATIVE STRESS; PROTEIN PHOSPHORYLATION; SKIN BRUISING; SMOKING;

ADMINISTRATION, INHALATION; BRONCHI; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GLUCOCORTICOIDS; HISTONE DEACETYLASES; HUMANS; INFLAMMATION; OXIDATIVE STRESS; PHOSPHORYLATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, GLUCOCORTICOID; REPRESSOR PROTEINS; TRANSCRIPTION, GENETIC;

EID: 27644572664     PISSN: 15463222     EISSN: None     Source Type: Journal    
DOI: 10.1513/pats.200504-035SR     Document Type: Conference Paper

References (92)

1. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004;350:2645-2653.
2. Barnes PJ. COPD: is there light at the end of the tunnel? Curr Opin Pharmacol 2004;4:263-272.
3. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 2003;22:672-688.
4. Barnes PJ. New concepts in chronic obstructive pulmonary disease. Annu Rev Med 2003;54:113-129.
5. Barnes PJ, Kleinert S. COPD: a neglected disease. Lancet 2004;364:564-565.
6. Lopez AD, Murray CC. The global burden of disease, 1990-2020. Nat Med 1998;4:1241-1243.
7. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361:449-456.
8. Barnes PJ, Ito K, Adcock IM. Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet 2004;363:731-733.
9. Chanez P, Vignola AM, O'Shaugnessy T, Enander I, Li D, Jeffery PK, Bousquet J. Corticosteroid reversibility in COPD is related to features of asthma. Am J Respir Crit Care Med 1997;155:1529-1534.
10. BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of the Standards of Care Committee of the BTS. Thorax 1997;52(suppl)5:S1-S28.
11. Celli BR. ATS standards for the optimal management of chronic obstructive pulmonary disease. Respirology 1997;2:S1-S4.
12. Siafakas NM, Tzanakis N. Diagnosis and treatment of chronic obstructive pulmonary disease: evidence-based medicine. Monaldi Arch Chest Dis 1998;53:704-708.
13. Pauwels RA, Buist AS, Ma P, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary. Respir Care 2001;46:798-825.
14. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000;343:269-280.
15. Saetta M, Turato G, Maestrelli P, Mapp CE, Fabbri LM. Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:1304-1309.
16. Boschetto P, Miniati M, Miotto D, Rambaldi A, Piola C, Caramori G, Papi A, Ciaccia A, De Rosa E, Fabbri LM, et al. Fixed airflow limitation due to predominant emphysema in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;165:C51.
17. Retamales I, Elliott WM, Meshi B, Coxson HO, Pare PD, Sciurba FC, Rogers RM, Hayashi S, Hogg JC. Amplification of inflammation in emphysema and its association with latent adenoviral infection. Am J Respir Crit Care Med 2001;164:469-473.
18. Montuschi P, Collins JV, Ciabattoni G, Lazzeri N, Corradi M, Kharitonov SA, Barnes PJ. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am J Respir Crit Care Med 2000;162:1175-1177.
19. Paredi P, Kharitonov SA, Leak D, Ward S, Cramer D, Barnes PJ. Exhaled ethane, a marker of lipid peroxidation, is elevated in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;162:369-373.
20. Macnee W. Oxidative stress and lung inflammation in airways disease. Eur J Pharmacol 2001;429:195-207.
21. Biernacki WA, Kharitonov SA, Barnes PJ. Increased leukotriene B4 and 8-isoprostane in exhaled breath condensate of patients with exacerbations of COPD. Thorax 2003;58:294-298.
22. Rahman I, van Schadewijk AA, Crowther AJ, Hiemstra PS, Stolk J, Macnee W, De Boer WI. 4-Hydroxy-2-nonenal, a specific lipid peroxidation product, is elevated in lungs of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002:166:490-495.
23. Rahman I. Oxidative stress, transcription factors and chromatin remodelling in lung inflammation. Biochem Pharmacol 2002;64:935-942.
24. Kostikas K, Papatheodorou G, Psathakis K, Panagou P, Loukides S. Oxidative stress in expired breath condensate of patients with COPD. Chest 2003;124:1373-1380.
25. Sugiura H, Ichinose M, Yamagata S, Koarai A, Shirato K, Hattori T. Correlation between change in pulmonary function and suppression of reactive nitrogen species production following steroid treatment in COPD. Thorax 2003;58:299-305.
26. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297-1303.
27. Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS. Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med 2001;345:941-947.
28. Halpern MT, Schmier JK, Van Kerkhove MD, Watkins M, Kalberg CJ. Impact of long-term inhaled corticosteroid therapy on bone mineral density: results of a meta-analysis. Ann Allergy Asthma Immunol 2004;92:201-207.
29. Jones PW, Willits LR, Burge PS, Calverley PM. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J 2003;21:68-73.
30. Sin DD, Golmohammadi K, Jacobs P. Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity. Am J Med 2004;116:325-331.
31. Keatings VM, Jatakanon A, Worsdell YM, Barnes PJ. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997;155:542-548.
32. Culpitt SV, Maziak W, Loukidis S, Nightingale JA, Matthews JL, Barnes PJ. Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:1635-1639.
33. Loppow D, Schleiss ME, Kanniess F, Taube C, Jorres RA, Magnussen H. In patients with chronic bronchitis a four week trial with inhaled steroids does not attenuate airway inflammation. Respir Med 2001;95:115-121.
34. Hattotuwa KL, Gizycki MJ, Ansari TW, Jeffery PK, Barnes NC. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am J Respir Crit Care Med 2002;165:1592-1596.
35. Culpitt SV, Rogers DF, Shah P, De Matos C, Russell RE, Donnelly LE, Barnes PJ. Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;167:24-31.
36. Russell RE, Culpitt SV, DeMatos C, Donnelly L, Smith M, Wiggins J, Barnes PJ. Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2002;26:602-609.
37. Russell RE, Thorley A, Culpitt S, Donnelly LE, Mattos CD, Wiggins J, Fitzgerald M, Barnes PJ. Alveolar macrophage-mediated elastolysis: roles of matrix metalloproteinases, cysteine, and serine proteases. Am J Physiol Lung Cell Mol Physiol 2002;283:L867-L873.
38. Lim S, Roche N, Oliver BG, Mattos W, Barnes PJ, Fan CK. Balance of matrix metalloprotease-9 and tissue inhibitor of metalloprotease-1 from alveolar macrophages in cigarette smokers: regulation by interleukin-10. Am J Respir Crit Care Med 2000;162:1355-1360.
39. Adcock IM. Glucocorticoids: new mechanisms and future agents. Curr Allergy Asthma Rep 2003;3:249-257.
40. Auphan N, Didonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of IκB synthesis. Science 1995;270:286-290.
41. Shim J, Karin M. The control of mRNA stability in response to extracellular stimuli. Mol Cells 2002;14:323-331.
42. Reichardt HM, Tuckermann JP, Gottlicher M, Vujic M, Weih F, Angel P, Herrlich P, Schutz G. Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor. EMBO J 2001;20:7168-7173.
43. Reichardt HM, Kaestner KH, Tuckermann J, Kretz O, Wessely O, Bock R, Gass P, Schmid W, Herrlich P, Angel P, et al. DNA binding of the glucocorticoid receptor is not essential for survival. Cell 1998;93:531-541.
44. Chook YM, Blobel G. Karyopherins and nuclear import. Curr Opin Struct Biol 2001;11:703-715.
45. Jans DA, Xiao CY, Lam MH. Nuclear targeting signal recognition: a key control point in nuclear transport? Bioessays 2000;22:532-544.
46. Ohno M, Fornerod M, Mattaj IW. Nucleocytoplasmic transport: the last 200 nanometers. Cell 1998;92:327-336.
47. Picard D, Yamamoto KR. Two signals mediate hormone-dependent nuclear localization of the glucocorticoid receptor. EMBO J 1987;6:3333-3340.
48. Jewell CM, Webster JC, Burnstein KL, Sar M, Bodwell JE, Cidlowski JA. Immunocytochemical analysis of hormone mediated nuclear translocation of wild type and mutant glucocorticoid receptors. J Steroid Biochem Mol Biol 1995;55:135-146.
49. Savory JA, Hsu B, Laquian IR, Giffin W, Reich T, Hache RG, Lefebvre YA. Discrimination between NL1- and NL2-mediated nuclear localization of the glucocorticoid receptor. Mol Cell Biol 1999;19:1025-1037.
50. Freedman ND, Yamamoto KR. Importin 7 and importin α/importin β are nuclear import receptors for the glucocorticoid receptor. Mol Biol Cell 2004;15:2276-2286.
51. Kumar S, Chaturvedi NK, Nishi M, Kawata M, Tyagi RK. Shuttling components of nuclear import machinery involved in nuclear translocation of steroid receptors exit nucleus via exportin-1/CRM-1 independent pathway. Biochim Biophys Acta 2004;1691:73-77.
52. Liu J, DeFranco DB. Protracted nuclear export of glucocorticoid receptor limits its turnover and does not require the exportin 1/CRM1-directed nuclear export pathway. Mol Endocrinol 2000;14:40-51.
53. Urnov FD, Wolffe AP. Chromatin remodeling and transcriptional activation: the cast (in order of appearance). Oncogene 2001;20:2991-3006.
54. Janknecht R, Hunter T. Versatile molecular glue: transcriptional control. Curr Biol 1996;6:951-954.
55. De Ruijter AJ, Van Gennip AH, Caron HN, Kemp S, Van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003;370:737-749.
56. Jenkins BD, Pullen CB, Darimont BD. Novel glucocorticoid receptor coactivator effector mechanisms. Trends Endocrinol Metab 2001;12:122-126.
57. Rosenfeld MG, Glass CK. Coregulator codes of transcriptional regulation by nuclear receptors. J Biol Chem 2001;276:36865-36868.
58. Li X, Wong J, Tsai SY, Tsai MJ, O'Malley BW. Progesterone and glucocorticoid receptors recruit distinct coactivator complexes and promote distinct patterns of local chromatin modification. Mol Cell Biol 2003;23:3763-3773.
59. Huang ZQ, Li J, Sachs LM, Cole PA, Wong J. A role for cofactor-cofactor and cofactor-histone interactions in targeting p300, SWI/SNF and Mediator for transcription. EMBO J 2003;22:2146-2155.
60. Lee HL, Archer TK. Prolonged glucocorticoid exposure dephosphorylates histone H1 and inactivates the MMTV promoter. EMBO J 1998;17:1454-1466.
61. McNally JG, Muller WG, Walker D, Wolford R, Hager GL. The glucocorticoid receptor: rapid exchange with regulatory sites in living cells. Science 2000;287:1262-1265.
62. Fletcher TM, Ryu BW, Baumann CT, Warren BS, Fragoso G, John S, Hager GL. Structure and dynamic properties of a glucocorticoid receptor-induced chromatin transition. Mol Cell Biol 2000;20:6466-6475.
63. Barnes PJ, Karin M. Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-1071.
64. Ito K, Barnes PJ, Adcock IM. Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1β-induced histone H4 acetylation on lysines 8 and 12. Mol Cell Biol 2000;20:6891-6903.
65. Swantek JL, Cobb MH, Geppert TD. Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for lipopolysaccharide stimulation of tumor necrosis factor alpha (TNF-α) translation: glucocorticoids inhibit TNF-α translation by blocking JNK/SAPK. Mol Cell Biol 1997;17:6274-6282.
66. Caelles C, Gonzalez-Sancho JM, Munoz A. Nuclear hormone receptor antagonism with AP-1 by inhibition of the JNK pathway. Genes Dev 1997;11:3351-3364.
67. Rider LG, Hirasawa N, Santini F, Beaven MA. Activation of the mitogen-activated protein kinase cascade is suppressed by low concentrations of dexamethasone in mast cells. J Immunol 1996;157:2374-2380.
68. Hirasawa N, Sato Y, Fujita Y, Mue S, Ohuchi K. Inhibition by dexamethasone of antigen-induced c-Jun N-terminal kinase activation in rat basophilic leukemia cells. J Immunol 1998;161:4939-4943.
69. Lasa M, Brook M, Saklatvala J, Clark AR. Dexamethasone destabilizes cyclooxygenase 2 mRNA by inhibiting mitogen-activated protein kinase p38. Mol Cell Biol 2001;21:771-780.
70. Lasa M, Abraham SM, Boucheron C, Saklatvala J, Clark AR. Dexamethasone causes sustained expression of mitogen-activated protein kinase (MAPK) phosphatase 1 and phosphatase-mediated inhibition of MAPK P38. Mol Cell Biol 2002;22:7802-7811.
71. Kassel O, Sancono A, Kratzschmar J, Kreft B, Stassen M, Cato AC. Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP-1. EMBO J 2001;20:7108-7116.
72. Rogatsky I, Logan SK, Garabedian MJ. Antagonism of glucocorticoid receptor transcriptional activation by the c-Jun N-terminal kinase. Proc Natl Acad Sci USA 1998;95:2050-2055.
73. Irusen E, Matthews JG, Takahashi A, Barnes PJ, Chung KF, Adcock IM. p38 Mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma. J Allergy Clin Immunol 2002;109:649-657.
74. Hu JM, Bodwell JE, Munck A. Cell cycle-dependent glucocorticoid receptor phosphorylation and activity. Mol Endocrinol 1994;8:1709-1713.
75. Zuo Z, Urban G, Scammell JG, Dean NM, McLean TK, Aragon I, Honkanen RE. Ser/Thr protein phosphatase type 5 (PP5) is a negative regulator of glucocorticoid receptor-mediated growth arrest. Biochemistry 1999;38:8849-8857.
76. Somers JP, DeFranco DB. Effects of okadaic acid, a protein phosphatase inhibitor, on glucocorticoid receptor-mediated enhancement. Mol Endocrinol 1992;6:26-34.
77. Hsu SC, Qi M, DeFranco DB. Cell cycle regulation of glucocorticoid receptor function. EMBO J 1992;11:3457-3468.
78. Galigniana MD, Housley PR, DeFranco DB, Pratt WB. Inhibition of glucocorticoid receptor nucleocytoplasmic shuttling by okadaic acid requires intact cytoskeleton. J Biol Chem 1999;274:16222-16227.
79. Bodwell JE, Hu JM, Orti E, Munck A. Hormone-induced hyperphos-phorylation of specific phosphorylated sites in the mouse glucocorticoid receptor. J Steroid Biochem Mol Biol 1995;52:135-140.
80. Bodwell JE, Hu JM, Hu LM, Munck A. Glucocorticoid receptors: ATP and cell cycle dependence, phosphorylation, and hormone resistance. Am J Respir Crit Care Med 1996;154:S2-S6.
81. Rogatsky I, Waase CL, Garabedian MJ. Phosphorylation and inhibition of rat glucocorticoid receptor transcriptional activation by glycogen synthase kinase-3 (GSK-3): species-specific differences between human and rat glucocorticoid receptor signaling as revealed through GSK-3 phosphorylation. J Biol Chem 1998;273:14315-14321.
82. Wallace AD, Cidlowski JA. Proteasome-mediated glucocorticoid receptor degradation restricts transcriptional signaling by glucocorticoids. J Biol Chem 2001;276:42714-42721.
83. Rahman I, Macnee W. Oxidative stress and regulation of glutathione in lung inflammation. Eur Respir J 2000;16:534-554.
84. Chalmers GW, Macleod KJ, Little SA, Thomson LJ, McSharry CP, Thomson NC. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax 2002;57:226-230.
85. Chaudhuri R, Livingston E, McMahon AD, Thomson L, Borland W, Thomson NC. Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma. Am J Respir Crit Care Med 2003;168:1308-1311.
86. Okamoto K, Tanaka H, Ogawa H, Makino Y, Eguchi H, Hayashi S, Yoshikawa N, Poellinger L, Umesono K, Makino I. Redox-dependent regulation of nuclear import of the glucocorticoid receptor. J Biol Chem 1999;274:10363-10371.
87. Matthews JG, Ito K, Barnes PJ, Adcock IM. Defective glucocorticoid receptor nuclear translocation and altered histone acetylation patterns in glucocorticoid-resistant patients. J Allergy Clin Immunol 2004;113:1100-1108.
88. Wedzicha JA, Donaldson GC. Exacerbations of chronic obstructive pulmonary disease. Respir Care 2003;48:1204-1213.
89. Bellettato C, Adcock IM, Ito K, Caramori G, Casolari P, Ciaccia A, Barnes PJ, Johnston SL, Papi A. Rhinovirus infection reduces glucocorticoid receptor nuclear translocation in airway epithelial cells. Eur Respir J 2003;22:565S.
90. Ito K, Ito M, Eliott WM, Cosio B, Caramori G, Kon OM, Barczyk A, Hayashi S, Adcock IM, Hogg JC, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 2005;52:1967-1976.
91. Ito K, Lim S, Caramori G, Chung KF, Barnes PJ, Adcock IM. Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression, and inhibits glucocorticoid actions in alveolar macrophages. FASEB J 2001;15:1110-1112.
92. Ito K, Hanazawa T, Tomita K, Barnes PJ, Adcock IM. Oxidative stress reduces histone deacetylase 2 activity and enhances IL-8 gene expression: role of tyrosine nitration. Biochem Biophys Res Commun 2004;315:240-245.